GlassScriptPhysician profile
Johnathan Keith Colton Jerris
NPI 1093310021
$2,374.20
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,308 · 2022: $1,066.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $422.06 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $407.48 | 2021-2022 | |
| Abbvie INC. | $245.05 | 2021-2022 | |
| Esperion Therapeutics, INC. | $178.95 | 2021 | |
| Sanofi-Aventis U.S. LLC | $175.20 | 2021-2022 | |
| Glaxosmithkline, LLC. | $145.65 | 2021-2022 | |
| Amarin Pharma, INC. | $104.57 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $103.98 | 2021-2022 | |
| Lilly USA, LLC | $76.96 | 2021-2022 | |
| Eisai INC. | $65.46 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $57.99 | 2021-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $50.92 | 2021-2022 | |
| Pfizer INC. | $50.87 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.31 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.13 | 2022 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $45.37 | 2022 | |
| Amgen INC. | $38.48 | 2021 | |
| Dexcom, INC. | $30.00 | 2022 | |
| Novartis Pharmaceuticals Corporation | $22.85 | 2022 | |
| Teva Pharmaceuticals USA, INC. | $22.73 | 2022 | |
| Edwards Lifesciences Corporation | $20.74 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $14.62 | 2021 | |
| Genentech USA, INC. | $0.83 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Johnathan Jerris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.